Patent ID: 7833736

Claim:
A method for determining whether a mammalian cancer is likely to be resistant or responsive to OSI-930 for the treatment of said cancer, said method comprising the step(s) of: (a) examining a biological sample from said cancer for the expression and/or activity of one or more marker proteins selected from the group consisting of: (i) Heat Shock Protein-27 (HSP-27) (SEQ ID NO: 1), (ii) Cortactin (SEQ ID NO: 2) (iii) Cdc25C (SEQ ID NO: 3), (iv) phospho-Cdc25C (Ser216) (SEQ ID NO: 3), (v) phospho-Cdc25C (Thr48) (SEQ ID NO: 3), (vi) phospho-MAPKAPK-2 (Thr334) (SEQ ID NO: 4), (vii) phospho-Cyclin E (Thr62) (SEQ ID NO: 5), (viii) Stathmin (SEQ ID NO: 6), (ix) phospho-ATF2 (Thr69) (SEQ ID NO: 7), (x) phospho-ATF2 (Thr71) (SEQ ID NO:7), (xi) phospho-Histone H3 (Thr3) (SEQ ID NO: 8), (xii) phospho-EIF-4B (Ser422) (SEQ ID NO: 9), (xiii) phospho-Rpb1 (Ser2) (SEQ ID NO: 10); and (xiv) phospho-Rpb1 (Ser5) (SEQ ID NO: 10); (b) identifying said cancer as being resistant to OSI-930 where there is decreased expression or activity of any of phospho-ATF2 (Thr69), phospho-ATF2 (Thr71), phospho-Histone H3 (Thr3), phospho-EIF-4B (Sr422), phospho-Rpb1 (Ser2), phospho-Rpb1 (Ser5), phospho-Cyclin-E (Thr62), cdc25C, phospho-cdc25C (Ser216), phospho-cdc25C (Thr48), or phospho-MAPKAPK-2 (Thr334) or increased expression or activity of HSP-27, Cortactin, or Stathmin relative to the same biomarker's expression or activity level in cancer that is responsive to OSI-930; or (c) identifying said cancer as being responsive to OSI-930 where there is increased expression or activity of any one of phospho-ATF2 (Thr69), phospho-ATF2 (Thr71), phospho-Histone H3 (Thr3), phospho-EIF-4B (Sr422), phospho-Rpb1 (Ser2), phospho-Rpb1 (Ser5), phospho-Cyclin-E (Thr62), cdc25C, phospho-cdc25C (Ser216), phospho-cdc25C (Thr48), or phospho-MAPKAPK-2 (Thr334) or decreased expression or activity of HSP-27, Cortactin, or Stathmin relative to the same biomarker's expression or activity level in cancer that is resistant to OSI-930.